Companies › CSL Behring
12 active drug programs in 20 registered trials: 8 Phase 2, 6 Phase 3, 5 Phase 4, 1 Phase 1; Hematology, Gastroenterology, Metabolic and endocrine, Cardiovascular; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IgPro10 (Privigen) Normal human immunoglobulin G (IVIG) | – | Phase 4 | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Dec 2029 |
| .Alpha.1-Proteinase Inhibitor Human (CE1226) Leukocyte elastase inhibitor | ELANE | Phase 4 | Alpha1 Antitrypsin Deficiency; Eosinophilic Esophagitis | Sep 2033 |
| Prothrombin Complex Concentrate (BE1116) Coagulation factor VII exogenous protein; Vitamin K-dependent protein S exogenous protein; Vitamin K-dependent protein C exogenous protein | F7, PROS1, PROC, F9, F2 | Phase 3 | Complex Cardiovascular Surgery With Cardiopulmonary Bypass; Cardiac Valve Disease; Hemophilia; Liver Cirrhosis | Apr 2027 |
| CSL511 Fibrinogen concentrate (human) Fibrinogen (clotting factor I) replacement | FGA | Phase 3 | Acquired Fibrinogen Deficiency | Jun 2027 |
| Etranacogene Dezaparvovec (CSL222) Coagulation factor IX exogenous protein | F9 | Phase 3 | Hemophilia B | Oct 2028 |
| IgPro20 Immune globulin replacement therapy | – | Phase 3 | Secondary Immune Deficiency; Multiple Myeloma | Sep 2029 |
| Lonoctocog Alfa Coagulation factor VIII exogenous protein | F8 | Phase 3 | Congenital Hemophilia A | – |
| Clazakizumab (CSL300) Interleukin-6 inhibitor | IL6 | Phase 2 | End Stage Kidney Disease; End Stage Kidney Disease (ESKD); COVID-19 Infection | Aug 2027 |
| CSL889 Human hemopexin | HPX | Phase 2 | Sickle Cell Disease Vaso-occlusive Crisis | Oct 2027 |
| Vamifeport Ferroportin stabilizer | FPN1 | Phase 2 | Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | Apr 2028 |
| Anumigilimab (CSL324) Granulocyte colony stimulating factor receptor antagonist | CSF3R | Phase 2 | Sickle Cell Disease | Aug 2028 |
| CSL787 human normal immunoglobulin G (IgG) inhalation solution | – | Phase 2 | Non-cystic Fibrosis Bronchiectasis | May 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04494724 | Clazakizumab (CSL300) | Phase 2 | COVID-19 Infection | Infectious disease | Dec 2020 |
| NCT06738485 | Lonoctocog Alfa | Phase 3 | Congenital Hemophilia A | Hematology | Sep 2026 |
| NCT06144125 | Prothrombin Complex Concentrate (BE1116) | Phase 4 | Cardiac Valve Disease | Hematology | Sep 2026 |
| NCT07406139 | Prothrombin Complex Concentrate (BE1116) | Phase 4 | Hemophilia | Hematology | Dec 2026 |
| NCT05667805 | Prothrombin Complex Concentrate (BE1116) | Phase 4 | Liver Cirrhosis | Gastroenterology | Jan 2027 |
| NCT05485155 | .Alpha.1-Proteinase Inhibitor Human (CE1226) | Phase 2 | Eosinophilic Esophagitis | Gastroenterology | Jan 2027 |
| NCT07094087 | Prothrombin Complex Concentrate (BE1116) | Phase 3 | Complex Cardiovascular Surgery With Cardiopulmonary Bypass | Cardiovascular | Apr 2027 |
| NCT06617897 | CSL511 Fibrinogen concentrate (human) | Phase 3 | Acquired Fibrinogen Deficiency | Hematology | Jun 2027 |
| NCT07619820 | Clazakizumab (CSL300) | Phase 1 | End Stage Kidney Disease (ESKD) | Cardiovascular | Aug 2027 |
| NCT06699849 | CSL889 | Phase 2 | Sickle Cell Disease Vaso-occlusive Crisis | Hematology | Oct 2027 |
| NCT07332091 | Vamifeport | Phase 2 | Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | Metabolic and endocrine | Apr 2028 |
| NCT07224360 | Anumigilimab (CSL324) | Phase 2 | Sickle Cell Disease | Hematology | Aug 2028 |
| NCT06003387 | Etranacogene Dezaparvovec (CSL222) | Phase 3 | Hemophilia B | Hematology | Oct 2028 |
| NCT07048262 | CSL787 | Phase 2 | Non-cystic Fibrosis Bronchiectasis | Respiratory | May 2029 |
| NCT06976476 | IgPro20 | Phase 2 | Multiple Myeloma | Oncology | May 2029 |
| NCT05485961 | Clazakizumab (CSL300) | Phase 2 | End Stage Kidney Disease | Cardiovascular | May 2029 |
| NCT07648264 | IgPro20 | Phase 3 | Secondary Immune Deficiency | Oncology | Sep 2029 |
| NCT03684018 | IgPro10 (Privigen) | Phase 4 | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Neurology | Dec 2029 |
| NCT07326592 | .Alpha.1-Proteinase Inhibitor Human (CE1226) | Phase 4 | Alpha1 Antitrypsin Deficiency | Metabolic and endocrine | Sep 2033 |
| NCT07080905 | Etranacogene Dezaparvovec (CSL222) | Phase 3 | Hemophilia B | Hematology | Oct 2033 |
F9 (2) ELANE (1) IL6 (1) FGA (1) CSF3R (1) FPN1 (1) HPX (1) F7 (1) PROS1 (1) PROC (1) F2 (1) F8 (1)
BioMarin Pharmaceutical Pfizer Roche Shanghai Xinzhi BioMed IntraBio Baxalta now part of Shire Biocad Regeneron Pharmaceuticals Onchilles Pharma Grifols Therapeutics
Grand Shuyang Life Sciences (Chengdu) Chongqing Peg-Bio Biopharm Kedrion Longbio Pharma Keymed Biosciences Co.Ltd
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.